Dr. Soon-Shiong's latest: CAR-NK cells, engineered to kill cancer. CAR stands for Chimeric Antigen Receptor, a tracking device tacked onto natural killer (NK) cells to kill cancer.
Dr. Pat says it's "agnostic" to cancer type because it's looking for ones that express PDL-1, which stands for Programmed Death-Ligand 1. PDL-1 evades the immune system, preventing cancer-cell death. But CAR-NK sees it, killing cancer-resistant cells frm the outside in.
Already FDA-approved: CAR-T therapies (tacked onto T cells) for blood cancers: leukemias, lymphomas, multiple myeloma.
#DrPatrick
Well here is the upcoming special at NewsNation - a discussion with patients who received the Bioshield and how it affected their lives. Thank you NewsNation leadership and Chris for bringing awareness to the country of this change in thinking of how we an now treat patients with cancer
A heartbeat that travels unbroken across continents, love emerges not as possession but as translation, a tender, tenacious dialogue between severed homelands and chosen futures.
Collaborating for the Central Island Studio Tour
Dr. Patrick Soon-Shiong spotlights the striking difference in regulatory treatment: while Merck’s checkpoint inhibitors sped through approval and now generate close to $32 billion in yearly revenue, novel biologics with strong safety profiles still face delays.
Despite rapid approvals, relapse and resistance remain significant challenges with checkpoint inhibitors. He urges a fair path forward for innovations like The Cancer BioShield platform from ImmunityBio—a strategy designed to help advanced cancer patients by restoring immune balance and reversing lymphopenia.
Dr. Soon-Shiong calls for rapid access to effective, evidence-backed immunotherapies, so hope and healing can reach more people without delay.
Working to explain to the world how and why Bioshield works.
T cells and NK cells kill cancer, that’s irrefutable.
Low NK cells and T cells means cancer grows, that’s irrefutable.
So if there is a drug available to boost NK and T cells then there is better chance to kill the cancer cell of any tumor type – That’s the how and it is that simple.
1. NK and T cells (lymphocytes) kill cancer… causation
2. Anktiva proliferates, grows and activates NK and T cells in the body... causation (and in the FDA approved label)
3. Adding Anktiva to current standards of care have shown prolonged survival in patients with cancer across multiple tumor types since it is treating the immune system... causation.
That is the HOW!
Anktiva the Bioshield is the first immunotherapy in history of medicine that is FDA approved with a mechanism of action to grow and supercharge NK and T cells in the body, generate memory T cells and restore the immune system without stimulating immunosuppressive T cells.
Now what's next? We can measure low NK and T cells (lymphopenia) with a simple blood test (ALC). This is no different than the same test measuring low red blood cells (anemia) or low neutrophils (neutropenia). Low NK and T cells are called lymphopenia. Ask your doctor what is my ALC? (absolute lymphocyte count)
Today, FDA has approved EPOGEN to treat anemia regardless of cancer type and has approved NEUPOGEN to treat neutropenia regardless of cancer type. So, based on the mechanism of action of ANKTIVA and the irrefutable causation that NK cells and T cells kill cancer, ANKTIVA should be enabled to treat patients with low NK and T cells (lymphopenia) regardless of tumor type. Especially since ANKTIVA, by activating NK and T cells (reversing lymphopenia) is the only FDA APPROVED mechanism of action in the label to generate MEMORY T CELLS. This supercharging of the immune system happens regardless of the cancer type and we have now shown in completed clinical trials across multiple tumor types including lung cancer (NSCLC), small-cell lung cancer (SCLC), urothelial carcinoma, head and neck cancer, melanoma, colorectal cancer, cervical cancer, renal cell carcinoma, gastric cancer, and hepatocellular carcinoma (manuscript in progress) that by increasing NK and T cells, we induce prolonged survival in patients who have failed all standards of care including current immunotherapy with checkpoint inhibitors. This mechanism of action has already been approved showing long term complete responses, but approved only for an orphan state of a subset of bladder cancer.
So, if ANKTIVA could receive the same consideration as EPOGEN and NEUPOGEN as an immune supportive agent, many patients could benefit now without having to fly to LA. I hope we can change that quickly and change the lives of countless of desperate patients in which all standards of care have failed. Working hard to change the course of cancer everyday.
The paradigm change is we are treating the immune system, regardless of its cancer type. Cancer is the symptom and the collapse of the immune system is the root cause.
Ask your doctor: “ what is my ALC?”and the reaction may be interesting . Next ask “what is my NLR ratio”?
Trying very hard to discuss this important science to evolve our thinking of how to treat our patients with cancer. Publication on lung cancer and 10 tumor types submitted.
Glioblastoma is medicine’s biggest challenge. For decades and still today the treatment involves surgery, followed by radiation with chemo followed by more chemo. At the end of this 90 percent of patients have a low lymphocyte count since the very treatment itself wipes out the NK and T cells.Invariably these patients relapse and are classified as recurrent GBM. For decades the treatment for recurrence is more chemo. Tomorrow we will release our first 5 patients with recurrent GBM with our chemo free Bioshield, NK cell therapy and an immune stimulating device. What the data shows is the effect and power of protecting and rescuing the immune system and what it has the potential to do for patients with this life threatening disease and for which there has been little to no advances to extend progression further and sadly early death. Excited to share.
@drpatrick Do you know when we can receive Bioshield as a preventative treatment please? I would like to rid my body of the spike protein residue from the vaccine and have this added protection against any further foreign invaders.